Assessing response in bone metastases in prostate cancer with diffusion weighted MRI

Area of Science:

• Oncology
• Radiology
• Medical Imaging

Background:

• Prostate carcinoma frequently metastasizes to bone.
• Assessing treatment response in bone metastases is crucial for patient management.
• Diffusion-weighted MRI offers potential for non-invasive response assessment.

Purpose of the Study:

• To evaluate if changes in apparent diffusion coefficient (ADC) of bone metastases differ between responders and progressors to chemotherapy.
• To determine the utility of ADC in assessing treatment response in prostate cancer bone metastases.

Main Methods:

• Diffusion-weighted MRI of the lumbar spine and pelvis was performed on 26 patients.
• Apparent diffusion coefficient (ADC) and ADC(slow) were calculated for bone metastases.
• Patients were classified as responders or progressors based on RECIST and PSA levels.

Main Results:

• A significant increase in mean ADC/ADC(slow) was observed in lesions for both responders and progressors.
• However, a considerable proportion of lesions showed a decrease in ADC, irrespective of treatment response.
• This heterogeneity suggests complex underlying biological changes.

Conclusions:

• Mean ADC is not a suitable standalone biomarker for evaluating chemotherapy response in prostate cancer bone metastases.
• The observed heterogeneity in ADC changes is likely due to the complex composition of bone marrow.
• Further research is needed to understand the factors influencing ADC variability in bone metastases.